Industry subdomain insight

How AI Is Used in Clinical Development in Pharma

This view tracks 17 documented AI deployments. Drug discovery is the most common use-case type with 4 cases, most often reporting a median −70% cost savings (n=5 metrics — early evidence).

Switch sub-industry

4 sub-industries
All PharmaDrug Discovery30Manufacturing and Quality18Clinical Development17Commercial Operations11

Executive brief

The most common AI use-case type here is Drug discovery, with 4 source-linked cases, 3 in the last 6 months. Deployments of this type report a median −70% cost savings (n=5 metrics — early evidence).

Cases

17

5 in the last 6 months

Innovativeness

3.0Differentiated

100% of evidence scored

Cases trend

Cases 2Agent 0

Early signal: Clinical documentation copilot — a promising impact-for-effort profile in limited evidence (2 cases).

Relative leverage

Which use-case types show the strongest leverage?

No type clears the higher-leverage threshold among the 4 scored types shown; Drug discovery (4 cases) is the largest high-impact investment signal.

Peer-relative view4 scored types shownMedian impact 4.0 · effort 3.7
Relative position:Higher leverageHigh-impact investmentsEfficient extensionsReview trade-offsDot size = scored casesTrending (last 6 months)
Higher leverage: Above-median impact with at-or-below-median effort among the types shown.HIGHER LEVERAGEHigh-impact investments: Above-median impact and effort among the types shown.STRATEGIC BETSEfficient extensions: At-or-below-median impact and effort among the types shown.EFFICIENT EXTENSIONSReview trade-offs: At-or-below-median impact with above-median effort among the types shown.REVIEW TRADE-OFFSHigher relative impact ↑Higher relative effort →Relative impact★★★

Use-case types

Tap a type to open

  1. 1

    Patient engagement

    High-impact investments · 3 cases · 3 scored

    Directional evidence

    Impact
    Effort
  2. 2

    Drug discovery

    High-impact investments · 4 cases · 4 scored

    Directional evidence

    Impact
    Effort
  3. 3

    Clinical documentation copilot

    Efficient extensions · 2 cases · 2 scored

    Directional evidence

    Impact
    Effort
  4. 4

    Medical document automation

    Efficient extensions · 2 cases · 2 scored

    Directional evidence

    Impact
    Effort
ⓘ How to read this chart

Each dot is one Clinical Development in Pharma use-case type, sitting at the mean build effort and business impact of its scored cases, positioned relative to the other scored types shown. The dashed crosshair is the peer median, so the split compares leverage within this view.

The dashed indigo zone marks higher leverage: above-median impact for at-or-below-median effort. Dot size reflects scored cases; impact and effort figures in the list are the true 1–5 averages.

Landscape

What are the most common AI use cases here?

The use-case types deployed most often in this view, ranked by volume and coloured by recent momentum.

7 use-case types

7 use-case types in view; Drug discovery leads with 4 cases, and 5 of the 14 cases shown were published in the last 6 months.

Bar colour = recent momentum (last 6 months), weighted by volume:Mostly olderGrowingRisingSurging
4Drug discovery3Patient engagement2Clinical documentation copilot2Medical document automation1Compliance copilot1Legal document automation1Risk assessment
Implementation

Do teams build, buy, or compose this?

How the documented deployments in this view were built — custom engineering (Build), an off-the-shelf assistant (Buy), or low-code assembly (Compose).

9 classified cases
BuildBuyComposeMixed

9 of 17 cases classified (53%) · Compare all use-case types

Full report

Expand any section for the detail behind the summary above.

Reported outcomes: Drug discovery — median −70% cost savings across 5 metrics (early evidence). Expand for the full ladder and qualitative themes.

Reported challenge examples: Algorithm bias leading to asymmetric treatment protocols (1 case), Analysts spent extensive time curating and cleaning data rather than generating value (1 case), Bias in clinical trials, leading to incomplete safety profiling and limited demographic representation (1 case), Build and operationalize AI and machine learning capabilities quickly in a complex global pharmaceutical organization (1 case), and Clinical data silos slowed down research and the ability to answer complex medical questions promptly (1 case). Evidence is still limited; expand to inspect the source cases.

Adoption pulse: 5 of the 17 cases in this view were published in the last 6 months. Expand for the adoption curve.

Questions answered here:

  • What are the most common AI use cases in Clinical Development in Pharma?
  • What results do Clinical Development in Pharma AI deployments report?

Related Insights

Next steps

Keep following this view or inspect the underlying case table.

Set alertsOpen case table